title: [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
abstract: Parkinson's disease is the second most common neurodegenerative disorder around the world. Levodopa has remained the "gold standard" of the therapy even several decades after its introduction. Chronic levodopa treatment is associated with the development of motor complications in most patients. Advanced Parkinson's disease is characterized by these complications: motor and non-motor fluctuation and disturbing dyskinesia. Continuous dopaminergic stimulation might reduce these complications. In advanced Parkinson's disease levodopa is still effective. In the treatment of this stage there are several advanced or device-aided therapies: apomorphine pump, deep brain stimulation and levodopa/carbidopa intestinal gel. Levodopa/carbidopa intestinal gel is an aqueous gel that can be delivered to the jejunum via a percutaneous gastrojejunostomy tube which is connected to an infusion pump dosing the levodopa gel continuously to the place of absorption. Levodopa/carbidopa gel infusion can be used as monotherapy, can be tested, can be used individually and this therapy is reversible. Several clinical trials demonstrated that levodopa/carbidopa intestinal gel therapy is of long-term benefit, improves the quality of life of the patients and can reduce motor fluctuation and dyskinesia.
authors.affiliation: Semmelweis University Department of Neurology, Budapest, Hungary. toth.adrian@med.semmelweis-univ.hu.
authors.forename: Adrián
authors.initials: A
authors.lastname: Toth
authors.forename: Helga
authors.initials: H
authors.lastname: Nagy
authors.forename: Judit
authors.initials: J
authors.lastname: Wacha
authors.forename: Dániel
authors.initials: D
authors.lastname: Bereczki
authors.forename: Annamária
authors.initials: A
authors.lastname: Takáts
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002230:Carbidopa / Q000008:administration & dosage* / Q000009:adverse effects; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000009:adverse effects; D020820:Dyskinesias / Q000209:etiology / Q000517:prevention & control*; D005774:Gastrostomy; D005782:Gels; D006801:Humans; D007422:Intestines; D007582:Jejunostomy; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy*; D011788:Quality of Life
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D005782:Gels; D007980:Levodopa; D002230:Carbidopa